Home » Topics » Disease categories and therapies » Respiratory

Respiratory
RSS

First patient dosed in phase II study of GC-4419 for COVID-19

Sep. 17, 2020

Profiling of JAK inhibitors AZD-4604 and AZD-0449 in translational rodent model of asthma

Sep. 15, 2020

FDA approves Trelegy Ellipta for asthma

Sep. 14, 2020

Phase III trial of Fasenra in nasal polyposis meets coprimary endpoints

Sep. 14, 2020

QBW-251: a CFTR potentiator in phase II for the treatment of COPD

Sep. 14, 2020

Results from a phase IIa POC trial of the oral adenosine A1 receptor antagonist PBF-680

Sep. 9, 2020

First phase I data presented for the neutrophil elastase inhibitor BI-1323495

Sep. 9, 2020

New personalized cystic fibrosis treatment treats Class V mutations

Sep. 9, 2020

Palobiofarma reports promising phase II data on PBF-680 for asthma

Sep. 7, 2020

Beijing Sanyou Liheze Biological Technology discovers potential stem cell therapy for COPD

Sep. 4, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...